Rinat_Neuroscience_Corporation

Rinat Neuroscience Corporation

Rinat Neuroscience Corporation

Biotechnology company

Rinat Neuroscience Corporation was a privately held biotechnology company that discovered and developed antibody-based drugs, including:

Rinat was founded in 2001 by Arnon Rosenthal,[12][13] who was also Rinat's president, chief scientific office and board director, and Patrick Lynn,[14] following a broad licensing agreement with Genentech,[15] and was acquired by Pfizer in 2006 for approximately $500M.[16][17] Rinat currently operates as an independent biotechnology unit within Pfizer's Worldwide R&D group in South San Francisco.[18]

References

  1. [1]
    Vastag, Brian. "Monoclonals expand into neural disorders". Nature.
  2. [2]
    Lane, Nancy E.; et al. (2010). "Tanezumab for the Treatment of Pain from Osteoarthritis of the Knee". New England Journal of Medicine. 363 (16). The New England Journal of Medicine: 1521–1531. doi:10.1056/NEJMoa0901510. PMC 6896791. PMID 20942668. S2CID 16950684.
  3. [3]
    "Ponezumab". ALZForum.
  4. [4]
    "Teva Completes Acquisition of Labrys: Opens Door to a Strong and Novel Migraine Prevention and Treatment Franchise within its CNS Portfolio". Business Wire/Nasdaq.
  5. [5]
    Carroll, John. "In biotech trifecta, startup lassos $31M, a CEO and a lead drug from Pfizer". FierceBiotech.
  6. [6]
    Leuty, Ron. "Migraine drug developer Labrys targeted by Teva in $825 million deal". San Francisco Business Times.
  7. [7]
    Berkrot, Bill; Beasley, Deena. "Experimental Pfizer cholesterol drug promising in study". Reuters.
  8. [8]
    "An Investigational Therapy for Geographic Atrophy in Age-Related Macular Degeneration".
  9. [9]
    Gumbiner, Barry; Esteves, Brooke; Dell, Vanessa; Joh, Tenshang; Garzone, Pamela D.; Forgie, Alison; Udata, Chandrasekhar (2018). "Single and multiple ascending-dose study of glucagon-receptor antagonist RN909 in type 2 diabetes". Endocrine. 62 (2): 371–380. doi:10.1007/s12020-018-1597-1. PMID 30203123. S2CID 52184370.
  10. [10]
    "REGN4018, a novel MUC16xCD3 bispecific T-cell engager for the treatment of ovarian cancer".
  11. [11]
    "FIH study of an OX40 agonist mAb PF-04518600 in adult patients with select advanced solid tumors".
  12. [12]
    "Arnon Rosenthal Ph.D. - Executive Profile". Bloomberg Businessweek. Archived from the original on October 26, 2014.
  13. [13]
    Leuty, Ron. "Alector snags funding in founder's latest attack on Alzheimer's". San Francisco Business Times.
  14. [14]
    "Patrick G. Lynn - Executive Profile". Bloomberg Businessweek. Archived from the original on October 26, 2014.
  15. [15]
    "Genentech and Rinat Neuroscience Announce Co-Development and Joint Commercialization Agreement for Anti-NGF Antibody for Acute and Chronic Pain". Genentech.
  16. [16]
    Pollack, Andrew. "Pfizer to Buy Rinat, a Biotechnology Drug Maker". New York Times.
  17. [17]
    "Pfizer to Expand Neuroscience Research with Acquisition of Biotech Company Rinat Neuroscience disorders". Pfizer. Archived from the original on 2015-09-24.
  18. [18]
    "Rinat". Pfizer. Archived from the original on 2014-09-01.


Stub icon

This United States corporation or company article is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Rinat_Neuroscience_Corporation, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.